Published in PLoS One on February 18, 2013
TGF-β: the master regulator of fibrosis. Nat Rev Nephrol (2016) 1.19
Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science (2002) 14.50
Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev (2001) 14.02
A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol (2005) 12.22
A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature (1995) 11.89
A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science (1994) 10.99
Signal transduction by the c-Jun N-terminal kinase (JNK)--from inflammation to development. Curr Opin Cell Biol (1998) 6.28
Rearrangements of the cytoskeleton and cell contacts induce process formation during differentiation of conditionally immortalized mouse podocyte cell lines. Exp Cell Res (1997) 6.24
p38 MAP kinase inhibition enables proliferation of adult mammalian cardiomyocytes. Genes Dev (2005) 3.88
Characterization of the structure and function of a new mitogen-activated protein kinase (p38beta). J Biol Chem (1996) 3.63
Essential role of p38alpha MAP kinase in placental but not embryonic cardiovascular development. Mol Cell (2000) 3.54
FGF and stress regulate CREB and ATF-1 via a pathway involving p38 MAP kinase and MAPKAP kinase-2. EMBO J (1996) 2.98
Characterization of the structure and function of the fourth member of p38 group mitogen-activated protein kinases, p38delta. J Biol Chem (1997) 2.47
Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum (2009) 2.38
Essential role for p38alpha mitogen-activated protein kinase in placental angiogenesis. Proc Natl Acad Sci U S A (2000) 2.30
Generation and characterization of p38beta (MAPK11) gene-targeted mice. Mol Cell Biol (2005) 2.19
ERK6, a mitogen-activated protein kinase involved in C2C12 myoblast differentiation. Proc Natl Acad Sci U S A (1996) 2.00
The primary structure of p38 gamma: a new member of p38 group of MAP kinases. Biochem Biophys Res Commun (1996) 1.99
Novel homologues of CSBP/p38 MAP kinase: activation, substrate specificity and sensitivity to inhibition by pyridinyl imidazoles. Biochem Biophys Res Commun (1997) 1.99
Deficiency of the stress kinase p38alpha results in embryonic lethality: characterization of the kinase dependence of stress responses of enzyme-deficient embryonic stem cells. J Exp Med (2000) 1.98
Endotoxin induces rapid protein tyrosine phosphorylation in 70Z/3 cells expressing CD14. J Biol Chem (1993) 1.93
p38gamma regulates the localisation of SAP97 in the cytoskeleton by modulating its interaction with GKAP. EMBO J (2005) 1.90
Role of p38 mitogen-activated protein kinase in a murine model of pulmonary inflammation. J Immunol (2000) 1.76
SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung. Am J Physiol Lung Cell Mol Physiol (2000) 1.75
Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis. Arthritis Rheum (2000) 1.72
Podocytes populate cellular crescents in a murine model of inflammatory glomerulonephritis. J Am Soc Nephrol (2004) 1.60
Differential, inducible gene targeting in renal epithelia, vascular endothelium, and viscera of Mx1Cre mice. Am J Physiol Renal Physiol (2002) 1.49
Pharmacological effects of SB 220025, a selective inhibitor of P38 mitogen-activated protein kinase, in angiogenesis and chronic inflammatory disease models. J Pharmacol Exp Ther (1998) 1.46
Initiation and evolution of interstitial leukocytic infiltration in experimental glomerulonephritis. Kidney Int (1991) 1.35
Podocyte involvement in human immune crescentic glomerulonephritis. Kidney Int (2005) 1.23
The p38 MAP kinase pathway and its biological function. Trends Cardiovasc Med (1998) 1.22
The role of p38alpha mitogen-activated protein kinase activation in renal fibrosis. J Am Soc Nephrol (2004) 1.12
Blockade of p38alpha MAPK ameliorates acute inflammatory renal injury in rat anti-GBM glomerulonephritis. J Am Soc Nephrol (2003) 1.08
The alpha-isoform of p38 MAPK specifically regulates arthritic bone loss. J Immunol (2009) 1.06
Inhibition of p38 mitogen-activated protein kinase is effective in the treatment of experimental crescentic glomerulonephritis and suppresses monocyte chemoattractant protein-1 but not IL-1beta or IL-6. J Am Soc Nephrol (2007) 1.01
Site-specific inhibition of glomerulonephritis progression by targeted delivery of dexamethasone to glomerular endothelium. Mol Pharmacol (2007) 0.99
Evolution of an immune suppressive macrophage phenotype as a product of P38 MAPK activation in polymicrobial sepsis. Shock (2001) 0.97
p38 Mitogen-activated protein kinase activation and cell localization in human glomerulonephritis: correlation with renal injury. J Am Soc Nephrol (2004) 0.95
Regulation of the oncogenic activity of the cellular src protein requires the correct spacing between the kinase domain and the C-terminal phosphorylated tyrosine (Tyr-527). Mol Cell Biol (1991) 0.91
Effects of p38 mitogen-activated protein kinase inhibition on anti-neutrophil cytoplasmic autoantibody pathogenicity in vitro and in vivo. Ann Rheum Dis (2010) 0.87
Selective p38MAPK isoform expression and activation in antineutrophil cytoplasmatic antibody-associated crescentic glomerulonephritis: role of p38MAPKalpha. Ann Rheum Dis (2007) 0.82
Expression of interferon-inducible Mx-proteins in patients with IgA nephropathy or Henoch-Schönlein purpura. Am J Kidney Dis (1999) 0.76
The pathogenesis of rheumatoid arthritis. N Engl J Med (2011) 12.16
Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med (2007) 9.44
Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol (2007) 8.47
Dickkopf-1 is a master regulator of joint remodeling. Nat Med (2007) 7.29
Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med (2012) 6.93
Nephron number in patients with primary hypertension. N Engl J Med (2003) 6.74
New loci associated with kidney function and chronic kidney disease. Nat Genet (2010) 5.58
Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest (2002) 5.42
Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc Natl Acad Sci U S A (2010) 5.05
Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J Clin Invest (2012) 4.31
Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature (2010) 4.01
Effects of donor pretreatment with dopamine on graft function after kidney transplantation: a randomized controlled trial. JAMA (2009) 3.83
Pathologic classification of diabetic nephropathy. J Am Soc Nephrol (2010) 3.61
Caspase-8 regulates TNF-α-induced epithelial necroptosis and terminal ileitis. Nature (2011) 3.61
Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum (2007) 3.02
The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med (2008) 2.99
Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE. J Exp Med (2008) 2.97
Blockade of receptor activator of nuclear factor-κB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus. Nat Med (2013) 2.93
Osteoclasts are essential for TNF-alpha-mediated joint destruction. J Clin Invest (2002) 2.85
FAN1 mutations cause karyomegalic interstitial nephritis, linking chronic kidney failure to defective DNA damage repair. Nat Genet (2012) 2.74
Regulatory T cells protect from local and systemic bone destruction in arthritis. J Immunol (2010) 2.70
CUBN is a gene locus for albuminuria. J Am Soc Nephrol (2011) 2.70
Autophagy regulates TNFα-mediated joint destruction in experimental arthritis. Ann Rheum Dis (2012) 2.66
Activation of canonical Wnt signalling is required for TGF-β-mediated fibrosis. Nat Commun (2012) 2.65
Prospective study on circulating MicroRNAs and risk of myocardial infarction. J Am Coll Cardiol (2012) 2.59
Mig6 is a negative regulator of EGF receptor-mediated skin morphogenesis and tumor formation. Nat Med (2006) 2.59
Periarticular bone structure in rheumatoid arthritis patients and healthy individuals assessed by high-resolution computed tomography. Arthritis Rheum (2010) 2.54
Role of the microvascular endothelium in progressive renal disease. J Am Soc Nephrol (2002) 2.51
Pathogenesis of ANCA-associated vasculitis: new possibilities for intervention. Am J Kidney Dis (2013) 2.41
Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies. Am J Pathol (2007) 2.41
Combined inhibition of tumor necrosis factor α and interleukin-17 as a therapeutic opportunity in rheumatoid arthritis: development and characterization of a novel bispecific antibody. Arthritis Rheumatol (2015) 2.39
I{kappa}B kinase (IKK){beta}, but not IKK{alpha}, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss. J Exp Med (2005) 2.21
B cells lacking the tumor suppressor TNFAIP3/A20 display impaired differentiation and hyperactivation and cause inflammation and autoimmunity in aged mice. Blood (2010) 2.17
Regulatory role of G protein-coupled estrogen receptor for vascular function and obesity. Circ Res (2009) 2.16
Cardiac involvement in Churg-Strauss syndrome: impact of endomyocarditis. Medicine (Baltimore) (2009) 2.14
Treg cells suppress osteoclast formation: a new link between the immune system and bone. Arthritis Rheum (2007) 2.12
High-sensitivity C-reactive protein and risk of nontraumatic fractures in the Bruneck study. Arch Intern Med (2006) 2.09
Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation (2004) 2.08
Relations of vitamin D status, gender and type 2 diabetes in middle-aged Caucasians. Acta Diabetol (2014) 2.07
Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis (2012) 2.06
12/15-lipoxygenase orchestrates the clearance of apoptotic cells and maintains immunologic tolerance. Immunity (2012) 2.06
Platelet-derived serotonin links vascular disease and tissue fibrosis. J Exp Med (2011) 2.05
Remnants of secondarily necrotic cells fuel inflammation in systemic lupus erythematosus. Arthritis Rheum (2009) 2.04
Epitope specificity determines pathogenicity and detectability in ANCA-associated vasculitis. J Clin Invest (2013) 1.99
The role of neutrophils in the induction of glomerulonephritis by anti-myeloperoxidase antibodies. Am J Pathol (2005) 1.97
Blockade of TNF-α rapidly inhibits pain responses in the central nervous system. Proc Natl Acad Sci U S A (2011) 1.95
Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction. Arthritis Rheum (2004) 1.94
Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis (2014) 1.88
Mechanisms of Disease: pathogenesis and treatment of ANCA-associated vasculitides. Nat Clin Pract Rheumatol (2006) 1.87
1,25-Dihydroxyvitamin D3 decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat. Am J Physiol Renal Physiol (2003) 1.86
Preconditional activation of hypoxia-inducible factors ameliorates ischemic acute renal failure. J Am Soc Nephrol (2006) 1.86
Myeloperoxidase attracts neutrophils by physical forces. Blood (2010) 1.84
Detection of "Candidatus Neoehrlichia mikurensis" in two patients with severe febrile illnesses: evidence for a European sequence variant. J Clin Microbiol (2010) 1.82
Vascular calcification in chronic kidney disease. Am J Kidney Dis (2004) 1.81
Early structural changes in cartilage and bone are required for the attachment and invasion of inflamed synovial tissue during destructive inflammatory arthritis. Ann Rheum Dis (2012) 1.81
Parietal epithelial cells participate in the formation of sclerotic lesions in focal segmental glomerulosclerosis. J Am Soc Nephrol (2011) 1.80
Alterations of beta-adrenergic signaling and cardiac hypertrophy in transgenic mice overexpressing TGF-beta(1). Am J Physiol Heart Circ Physiol (2002) 1.79
EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis. Ann Rheum Dis (2012) 1.78
Eotaxin-3 in Churg-Strauss syndrome: a clinical and immunogenetic study. Rheumatology (Oxford) (2011) 1.74
How antirheumatic drugs protect joints from damage in rheumatoid arthritis. Arthritis Rheum (2008) 1.74
Protective role of endothelial nitric oxide synthase. J Pathol (2003) 1.73
Histones from dying renal cells aggravate kidney injury via TLR2 and TLR4. J Am Soc Nephrol (2012) 1.73
Human homozygous R403W mutant cardiac myosin presents disproportionate enhancement of mechanical and enzymatic properties. J Mol Cell Cardiol (2004) 1.72
Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum (2002) 1.72
Complement factor C5a mediates renal ischemia-reperfusion injury independent from neutrophils. J Immunol (2003) 1.71
Mouse gridlock: no aortic coarctation or deficiency, but fatal cardiac defects in Hey2 -/- mice. Curr Biol (2002) 1.70
Are spondylarthritides related but distinct conditions or a single disease with a heterogeneous phenotype? Arthritis Rheum (2013) 1.69
Transforming growth factor-beta mediates balance between inflammation and fibrosis during plaque progression. Arterioscler Thromb Vasc Biol (2002) 1.69
Bacterial infections in Wegener's granulomatosis: mechanisms potentially involved in autoimmune pathogenesis. Curr Opin Rheumatol (2011) 1.68
Risk of infections in rheumatoid arthritis patients treated with tocilizumab. Rheumatology (Oxford) (2011) 1.68
Genome-wide association and functional follow-up reveals new loci for kidney function. PLoS Genet (2012) 1.68
p27(Kip1) Knockout mice are protected from diabetic nephropathy: evidence for p27(Kip1) haplotype insufficiency. Kidney Int (2005) 1.67
The value of extended transurethral resection of bladder tumour (TURBT) in the treatment of bladder cancer. BJU Int (2012) 1.67
Neutralisation of Dkk-1 protects from systemic bone loss during inflammation and reduces sclerostin expression. Ann Rheum Dis (2010) 1.67
PPARβ/δ governs Wnt signaling and bone turnover. Nat Med (2013) 1.66
Rho-kinase inhibition blunts renal vasoconstriction induced by distinct signaling pathways in vivo. J Am Soc Nephrol (2003) 1.66
Aggravation of anti-myeloperoxidase antibody-induced glomerulonephritis by bacterial lipopolysaccharide: role of tumor necrosis factor-alpha. Am J Pathol (2005) 1.65
Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis Rheum (2009) 1.65
Emergence of dendritic cells in rupture-prone regions of vulnerable carotid plaques. Atherosclerosis (2004) 1.64
Hypertension induces somatic cellular senescence in rats and humans by induction of cell cycle inhibitor p16INK4a. Hypertension (2008) 1.63
Hypertrophy of podocytes: a mechanism to cope with increased glomerular capillary pressures? Kidney Int (2005) 1.63
Bone erosions and bone marrow edema as defined by magnetic resonance imaging reflect true bone marrow inflammation in rheumatoid arthritis. Arthritis Rheum (2007) 1.62
TNF-induced structural joint damage is mediated by IL-1. Proc Natl Acad Sci U S A (2007) 1.61
Wnt inhibitory factor 1 deficiency uncouples cartilage and bone destruction in tumor necrosis factor α-mediated experimental arthritis. Arthritis Rheum (2013) 1.59
Tumour necrosis factor blockers and structural remodelling in ankylosing spondylitis: what is reality and what is fiction? Ann Rheum Dis (2007) 1.58
Blockade of the hedgehog pathway inhibits osteophyte formation in arthritis. Ann Rheum Dis (2012) 1.58